Floatz logo

23me-00610

Cancer With A High Tumor Mutational Burden

23andMe, Inc.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Cancer With A High Tumor Mutational Burden cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Medicenna Therapeutics, Inc.
Phase 1/2CCC
Mdna11
Medicenna Therapeutics, Inc.
Phase 1/2CCC

Same molecule, other indications

23me-00610 is also rated in:

MSI-H CancerDormant
CC
Indicative ·
47 / 100
View asset →
primary peritoneal carcinomaDormant
CC
Indicative ·
45 / 100
View asset →
small cell lung carcinomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →